Pfizer to sell all its drugs in 45 low-income countries at non-profit price
Pfizer’s not-for-profit pricing pledge now spans all 500 of its medicines — including chemotherapy and oral cancer treatments — across 45 of the world’s lowest-income countries. That’s a major expansion of an accord the company launched in 2022, which originally covered only patented drugs. By including off-patent medicines too, Pfizer is acknowledging that even decades-old cancer treatments often remain out of reach where generic supply chains never took hold. For patients across much of sub-Saharan Africa and South Asia, where cancer and heart disease are rising fast, this could quietly move the floor on what’s possible. And when the world’s largest drugmaker makes a move this broad, the rest of the industry tends to notice.
